ELVN : Insider Transactions for Enliven Therapeutics Ord Shs | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Enliven Therapeutics Ord Shs (ELVN)

$0.00 0.00 (0.00%) as of 4:30 Tue 11/30

Download

Exchange:

N/A

Security Type:

Common

Shares Out:

50,240,000

Market Cap:

N/A

Last Volume:

0

Avg Vol:

0

52 Week Range:

$0 - $0

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -

Company Profile IMARA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, and other serious diseases. Co.'s pipeline is built on the differentiated therapeutic potential of its primary product candidate, tovinontrine (IMR-687), which is an oral, small molecule inhibitor of phosphodiesterase-9. Tovinontrine is in Phase 2b clinical development for the treatment of sickle cell disease and ss-thalassemia. Co. is also developing IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2–related factor 2.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	104,501	183,852	480,042	4,850,661
Total Sell Value	$2,031,985	$3,798,534	$11,589,838	$94,767,802
Total People Sold	4	4	7	10
Total Sell Transactions	18	30	78	157
End Date	2025-03-30	2024-12-27	2024-06-28	2023-06-29

Adjust Filter Settings

Records found: 369

Page 1 of 15

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICER

• – –

2025-06-20

4

AS

$21.40

$267,458

I/I

(12,500)

965,188

-

PRESIDENT AND CEO

• • –

2025-06-17

4

AS

$22.08

$277,292

I/I

(12,500)

952,892

-

CHIEF FINANCIAL OFFICER

• – –

2025-06-13

4

AS

$22.55

$67,655

D/D

(3,000)

23,000

-

CHIEF FINANCIAL OFFICER

• – –

2025-06-13

4

OE

$2.48

$7,440

D/D

3,000

26,000

-

CHIEF OPERATING OFFICER

• – –

2025-06-09

4

AS

$20.33

$135,574

I/I

(6,667)

303,309

-

PRESIDENT AND CEO

• • –

2025-06-03

4

AS

$20.05

$150,352

I/I

(7,500)

965,392

-

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICER

• – –

2025-06-03

4

AS

$20.03

$150,220

I/I

(7,500)

977,688

-

CHIEF FINANCIAL OFFICER

• – –

2025-05-27

4

AS

$16.18

$52,593

D/D

(3,250)

23,000

-

CHIEF FINANCIAL OFFICER

• – –

2025-05-27

4

OE

$2.48

$8,060

D/D

3,250

26,250

-

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICER

• – –

2025-05-19

4

AS

$16.31

$81,534

I/I

(5,000)

985,188

-

PRESIDENT AND CEO

• • –

2025-05-19

4

AS

$16.49

$82,453

I/I

(5,000)

972,892

-

CHIEF OPERATING OFFICER

• – –

2025-05-07

4

AS

$18.30

$122,579

I/I

(6,667)

309,976

-

PRESIDENT AND CEO

• • –

2025-05-02

4

AS

$20.00

$43,409

I/I

(2,170)

977,892

-

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICER

• – –

2025-05-02

4

AS

$20.01

$49,424

I/I

(2,470)

990,188

-

PRESIDENT AND CEO

• • –

2025-05-01

4

AS

$20.08

$107,007

I/I

(5,330)

980,062

-

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICER

• – –

2025-05-01

4

AS

$20.07

$100,966

I/I

(5,030)

992,658

-

CHIEF FINANCIAL OFFICER

• – –

2025-04-28

4

AS

$18.68

$60,738

D/D

(3,250)

23,000

-

CHIEF FINANCIAL OFFICER

• – –

2025-04-28

4

OE

$2.48

$8,060

D/D

3,250

26,250

-

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICER

• – –

2025-04-21

4

AS

$16.03

$80,366

I/I

(5,000)

997,688

-

PRESIDENT AND CEO

• • –

2025-04-17

4

AS

$16.42

$82,096

I/I

(5,000)

985,392

-

CHIEF OPERATING OFFICER

• – –

2025-04-07

4

AS

$17.81

$120,269

I/I

(6,667)

316,643

-

CHIEF FINANCIAL OFFICER

• – –

2025-03-27

4

AS

$21.33

$69,321

D/D

(3,250)

23,000

-

CHIEF FINANCIAL OFFICER

• – –

2025-03-27

4

OE

$2.48

$8,060

D/D

3,250

26,250

-

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICER

• – –

2025-03-19

4

AS

$20.61

$257,575

I/I

(12,500)

1,002,688

-

PRESIDENT AND CEO

• • –

2025-03-17

4

AS

$20.83

$260,320

I/I

(12,500)

990,392

-

369 Records found	1 2 3 4 5 6 7 8 9 Next	Page 1 of 15

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2025 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.